Pulmatrix, Inc. (PULM) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Pulmatrix, Inc. in 2026. The next earnings report is expected on November 5, 2026.
Next earnings date
05 Nov 2026
In 78 days
EPS estimate
—
Revenue estimate
—
Past earnings
No dividend history available.
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Pulmatrix, Inc. (PULM) is scheduled to report earnings on November 5, 2026.
Pulmatrix, Inc. (PULM) last reported earnings on August 13, 2026.
Pulmatrix, Inc. (PULM) is listed on Nasdaq.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.